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Enhanced Ghrelin Levels and 
Hypothalamic Orexigenic AgRP 
and NPY Neuropeptide Expression 
in Models of Jejuno-Colonic Short 
Bowel Syndrome
Laura Gillard1, Lore Billiauws1,2, Bogdan Stan-Iuga1, Lara Ribeiro-Parenti1,3, Anne-
Charlotte Jarry1, Jean-Baptiste Cavin1, Françoise Cluzeaud1, Camille Mayeur4, 
Muriel Thomas4, Jean-Noël Freund5, Jean-Marc Lacorte6,7,8, Maude Le Gall1, André Bado1, 
Francisca Joly1,2,$ & Johanne Le Beyec1,7,8,$
Short bowel syndrome (SBS) patients developing hyperphagia have a better outcome. Gastrointestinal 
endocrine adaptations help to improve intestinal functions and food behaviour. We investigated 
neuroendocrine adaptations in SBS patients and rat models with jejuno-ileal (IR-JI) or jejuno-colonic 
(IR-JC) anastomosis with and without parenteral nutrition. Circulating levels of ghrelin, PYY, GLP-
1, and GLP-2 were determined in SBS rat models and patients. Levels of mRNA for proglucagon, 
PYY and for hypothalamic neuropeptides were quantified by qRT-PCR in SBS rat models. Histology 
and immunostaining for Ki67, GLP-1 and PYY were performed in SBS rats. IR-JC rats, but not IR-JI, 
exhibited significantly higher crypt depths and number of Ki67-positive cells than sham. Fasting and/
or postprandial plasma ghrelin and PYY concentrations were higher, or tend to be higher, in IR-JC rats 
and SBS-JC patients than in controls. Proglucagon and Pyy mRNA levels were significantly enhanced in 
IR-JC rats. Levels of mRNA coding hypothalamic orexigenic NPY and AgRP peptides were significantly 
higher in IR-JC than in sham rats. We demonstrate an increase of plasma ghrelin concentrations, major 
changes in hypothalamic neuropeptides levels and greater induction of PYY in SBS-JC rats and patients 
suggesting that jejuno-colonic continuity creates a peculiar environment promoting further gut-brain 
adaptations.
Short bowel syndrome (SBS) results from extensive resection of the small intestine. It is the leading cause of 
chronic intestinal failure and is treated principally by parenteral nutrition (PN). The degree of malabsorption 
depends on both the extent of the resection and the anatomy of the remnant bowel. Adaptive phenomena occur 
during the two to three years following the surgery and are characterized by improvements in intestinal absorp-
tion1,2, increase of hormonal secretion3,4, development of an hyperphagia2,5 and dysbiosis of the gut microbiota6–8. 
These changes, which are highly variable and unique to each patient, may facilitate weaning off of PN. Oral intake 
plays a major role in these adaptations9 as does the presence of the terminal ileum and/or colon.
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Gut hormones are key factors in this spontaneous intestinal adaptation10. Increased secretions of glucagon-like 
peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) have been reported in preclinical models11,12 and in 
SBS patients with the colon in continuity3, but not in SBS patients with jejunostomy (i.e. with no colon and 
no ileum)4,13 These hormones are secreted, together with Peptide YY (PYY), by the enteroendocrine L cells of 
the ileum and colon, in response to nutrient stimulation14. They play key roles in orchestrating gastrointestinal 
functions, such as intestinal trophicity12, expression of intestinal nutrient transporters10,15,16 and gastro-intestinal 
motility4,17. The role of GLP-2 in these intestinal functions has been largely documented18 in SBS patients and its 
therapeutic use (in the recombinant form of Teduglutide) has now been approved in adults with SBS dependent 
on PN. At last, PYY and GLP-1 are considered to be molecular mediators of the ileal brake19. They inhibit gastric 
emptying and intestinal transit, thereby increasing the time for the nutrients to be absorbed by the intestinal 
mucosa.
The development of hyperphagia, which increases over time in SBS patients after reestablishment of colonic 
continuity2, makes it possible to decrease dependence on PN by increasing net nutrient absorption2. It is associ-
ated with a good prognosis for the weaning off of PN2,20. The molecular and physiological mechanisms under-
lying the development of this compensatory overeating in SBS patients remain unknown. In addition to their 
gastro-intestinal effects, gut hormones (such as CCK, PYY, GLP-1 and ghrelin) participate in the regulation of 
appetite and food intake14. Ghrelin, is the unique orexigenic gut hormone21,22. Plasma ghrelin levels increase 
before meal, stimulating hunger and meal initiation, and then decrease after the meal21. These peripheral gastro-
intestinal signals are integrated into the hypothalamus, which contains two populations of neurons: orexigenic 
neurons co-expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) and anorexigenic neurons 
co-expressing pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART)14,23 
Ghrelin increases food intake through the activation of hypothalamic orexigenic neurons24. Little, if anything, is 
known about the expression of these neuropeptides in preclinical models of intestinal resection. Only one study 
has reported data for the fasting concentrations of ghrelin and PYY in SBS patients with adaptive hyperphagia but 
their postprandial levels were not evaluated25. Finally, the measure of circulating gut hormones is recognized of 
great interest for the follow-up of patients with gastrointestinal pathology and/or surgery. However their baseline 
and postprandial concentrations are rarely evaluated in combined panels in SBS patients with or without ileum 
nor compared with control subjects and little is known about what the colon or the ileum specifically brings to 
intestinal endocrine adaptation in SBS.
To address the colonic cellular and molecular mechanisms of adaptive hormonal secretions, we set up two rat 
models of extensive intestinal resection with colon in continuity and with or without a resected ileum. We use 
these models to analyze food intake, hypothalamic neuropeptides expression and to evaluate gastro-intestinal 
production and secretion of gut hormones (ghrelin, PYY, GLP-1 and GLP-2) in comparison with sham-operated 
animals. We further analyzed the clinical relevance of hormonal adaptation in relation to food intake (fasting and 
post-prandial gut hormone secretion) in jejuno-colonic and jejuno-ileal SBS patients.
Results
Preclinical models. Characteristics of rat models. All rats were on oral nutrition with free access to food, 
but a group of IR-JC rats received also PN to partially compensate for their malabsorption. Seven days after sur-
gery, sham rats had gained 6% of their pre-operative weight, whereas IR jejuno-ileal (IR-JI) and jejuno-colonic 
(IR-JC) rats had lost 14% and 29% of their pre-operative weight, respectively (Fig. 1B). IR jejuno-colonic rats 
under enteral and parenteral nutrition (IR-JC PN) had lost 17% of their pre-operative weight without increas-
ing their food intake suggesting that PN (12 kcal/day) was beneficial for the nutritional status of the IR-JC rats. 
Total calorie intake (oral intake and parenteral nutrition) (Fig. 1C) increased in all groups during the experiment 
although it remained lower in IR-JC rats. Consistent with their weight loss, plasma leptin and albumin levels were 
significantly lower in IR-JC and IR-JI groups than in the sham group (P < 0.05) (Fig. 1D,E),and tended to be lower 
for leptin in IR-JC PN group.
Histological examination of the colon mucosa (Fig. 2A) showed that IR-JC rats had significantly deeper 
colonic crypts compared to sham rats (P < 0.001 IR JC vs sham and P < 0.05 IR JC-PN vs sham) (Fig. 2B), 
reflecting morphological adaptation. In addition they displayed higher number of Ki67-positive cells per crypt 
(Fig. 2A,C) (P < 0.05) than sham rats. On the contrary IR-JI rats were not significantly different from sham rats. 
The proliferative index was not significantly different between groups suggesting that the epithelial homeostasis 
was recovered at that post-operative time (Fig. 2D)
PAS mucin staining and Muc2 immunostaining of the residual colon mucosa of IR-JC rat, revealed an increase 
of mucus production compared to sham rat (Fig. 2E,F), as previously described for other preclinical models 
of large intestinal resection26. This greater number of goblet cells is probably a consequence of the increase of 
the crypt depth observed in IR-JC rats. The density of these cells was not modified in IR-JC compared to sham 
(Fig. 2F).
Higher plasma concentrations of gut hormones in rat models of SBS. Fasting plasma ghrelin concentration was 
significantly higher in IR-JC rats with and without PN than in sham rats (P < 0.01) (Fig. 3A), whereas no such dif-
ference was observed in IR-JI rats. Fasting plasma GLP-1 and GLP-2 concentrations (Fig. 3B,C) were also higher 
in IR-JC rats with and without PN (P < 0.05 and < 0.01, respectively versus sham, for GLP-2). Fasting plasma PYY 
concentration, which was barely detectable in sham rats, was increased in IR-JI rats and was further enhanced in 
IR-JC rats (P < 0.05) (Fig. 3D). Unfortunately we were not able to determine plasma PYY in IR-JC PN rats and 
plasma GLP-1 and GLP-2 in IR-JI rats due to technical problems. However the higher plasma GLP-1, GLP-2 and 
PYY levels observed in overnight fasted rats were also found in non-fasted IR-JC rats (P < 0.01 or P < 0.05 vs 
sham) (Supplemental Figure S1).
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No change in the densities of PYY and GLP-1 positive cells but higher levels of mRNA coding for proglucagon and 
PYY. We investigated whether the elevation of these hormone levels was due to an increase in the number of 
enteroendocrine cells producing them and/or an increase in the hormone production by these cells. The den-
sity of GLP-1 positive cells was similar in the 3 groups of IR rats and in sham rats (Fig. 4A,C). The density of 
PYY-positive cells was unchanged in IR-JC rats without PN, and slightly lower in the colon mucosa of IR-JC rats 
with PN (Fig. 4B,D). Nevertheless, since the crypt depth is enhanced by 50% (Fig. 2A,B), this means that the total 
number of these cells will be increased similarly. The levels of mRNA coding for Gcg and PYY were 4 and 3-fold 
higher, respectively, in the colon mucosa of IR-JC rats than sham rats (P < 0.001) (Fig. 4E,F). IR-JC rats with PN 
had mRNA levels coding for Gcg and PYY similar to those observed in sham and IR-JI rats, but lower than those 
observed in IR-JC rats (P < 0.05).
Higher levels of mRNA coding for hypothalamic orexigenic neuropeptides (AgRP, NPY) and lower levels of mRNA 
coding for anorexigenic neuropeptides (POMC, CART) in rat models of SBS. We investigated changes in the levels 
Figure 1. Body weight loss, plasma leptin levels and histological adaptation of the remaining colon mucosa 
after intestinal resection in rats. (A) Schematic representation of the surgeries and colonic tissue collections  
at day 7 post-surgery. Length of resected or remnant part of intestinal segments are not proportional.  
(B) Comparative time-dependent body weight loss represented as percent of the preoperative weight and  
(C) total calorie intake (oral intake and parenteral nutrition) in IR jejuno-ileal (IR-JI), IR jejuno-colonic  
(IR-JC), IR jejuno-colonic PN (IR-JC PN) and sham-operated (Sham) rats during 7 days after surgery. Black  
box corresponds to the period of the postoperative care. (D,E) Plasma levels of leptin (D) and albumin (E) in 
the same groups. Data are represented as mean ± SEM of n = 6 for sham, n = 4 to 6 for IR jejuno-ileal, n = 10 for 
IR jejuno-colonic, n = 5 to 6 for IR jejuno-colonic with PN. * P < 0.05, * * P < 0.01, vs sham-operated rats based 
on non-parametric Kruskal-Wallis test followed by Dunn’s adjusted multiple comparisons.
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of hypothalamic neuropeptides after intestinal resection by analyzing mRNA levels for orexigenic (AgRP and 
NPY) and anorexigenic (CART and POMC) neuropeptides within the hypothalamus (Fig. 5).
IR-JC rats had significantly higher mRNA levels of AgRP and NPY than the sham rats (P < 0.001) (Fig. 5A,B). 
These levels were also significantly higher in IR-JC rats with PN than in sham rats (P < 0.05). Actually, mRNA 
levels of hypothalamic neuropeptides were not statistically different in IR-JC rats with PN or without PN.
Figure 2. histological adaptation of the remaining colon mucosa after intestinal resection in rats.  
(A) Representative photomicrographs of colon mucosa of Sham, IR jejuno-ileal (JI), IR jejuno-colonic (JC)  
and IR jejuno-colonic with PN (JC-PN) rats immunostained with an anti-Ki67 antibody. (B) Measurement of 
colon mucosa crypt depth in μ m (at least 5 crypts analyzed by rat). (C) Quantification of Ki67 positive cells per 
crypt (at least 5 crypts analyzed by rat), (D) density of Ki67 positive cells expressed as number of Ki67 positive 
cells per 100 μ m of crypt. (E,F) Representative photomicrographs of colon mucosa of sham and IR-JC rats 
stained with Periodic Acid Schiff (PAS) (E) and Representative photomicrographs of colon mucosa of sham and 
IR-JC rats immunostained with anti-Muc2 antibody (F) with quantification of Muc2 positive cells per area in 
mm2. Data are represented as mean ± SEM of n = 6 for sham, n = 4 to 6 for IR jejuno-ileal, n = 10 for IR jejuno-
colonic, n = 5 to 6 for for IR jejuno-colonic with PN. * P < 0.05, * * P < 0.01, vs sham-operated rats based on 
non-parametric Kruskal-Wallis test followed by Dunn’s adjusted multiple comparisons. Scale bar: 50 μ m.
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Conversely, IR-JC rats (with or without PN) had significantly lower mRNA levels of POMC than the animals 
of the sham group (P < 0.001 and P < 0.05 respectively) (Fig. 5C,D). The decrease of mRNA levels coding CART 
was more subtle (P < 0.05). These results show that jejuno-colonic continuity induces substantial changes in the 
expression of hypothalamic neuropeptides controlling food intake and PN only slightly compensates this effect.
Clinical study. Characteristics of SBS patients and control subjects. We studied SBS patients (medians for 
clinical characteristics are in Table 1) with jejuno-ileal (SBS-JI, N = 5) or jejuno-colonic (SBS-JC, N = 4) anasto-
mosis. All SBS patients were considered to be in a steady state and had a remnant small bowel of less than 80 cm in 
length. All had normal albumin and prealbumin levels. Their concentration of plasma leptin was normal or low 
(Table 1). The average of total oral intake was 2271 (± 288) kcal/day equivalent to 1.8 (± 0.73) times their resting 
energy expenditure (REE). Six SBS patients were considered to have a high level of oral intake or hyperphagia2, 
i.e. with oral intake > 1.5 time their REE (Table 1). Six of the SBS patients were dependent on PN (average of 
1181 ± 787 kcal/perfusion). Patient’s gut hormone concentrations were compared with those of healthy subjects 
(C, N = 5) that were disease-free with normal eating behaviour.
Higher plasma concentrations of active ghrelin, GLP-1, GLP2 and PYY in SBS patients. As expected, active ghrelin 
levels decreased 30 minutes after eating the calibrated meal in control subjects, remaining low for at least 90 min-
utes (Supplemental Figure S2A). Fasting active ghrelin levels tended to be higher in SBS patients than in healthy 
controls (Supplemental Figure S2A),were significantly higher at 30 minutes in SBS patients (P < 0.05 vs controls) 
and decreased only at 90 minutes. The calculated total area under the curve (AUC), reflecting the absolute levels 
of ghrelin and the post-prandial response, was significantly greater (by a factor of two, P < 0.05 vs controls) in 
SBS patients (Supplemental Figure S2B). Distinguishing jejuno-colonic from jejuno-ileal SBS patients revealed 
that fasting active ghrelin elevation tended to be higher for jejuno-colonic SBS patients than for jejuno-ileal 
SBS patients and controls (Fig. 6A). Jejuno-colonic SBS patients exhibited a delayed meal-induced inhibition 
Figure 3. Increased levels of plasma gut hormones after intestinal resection in rats. Fasting plasma levels of 
ghrelin (A), GLP-1 (B) GLP-2 (C) and PYY (D) in IR jejuno-ileal (JI), IR jejuno-colonic (JC), IR jejuno-colonic 
with PN (JC-PN) and sham-operated (Sham) overnight fasted rats 7 days after surgery. Data are represented 
as mean ± SEM of n = 6 for sham, n = 4 or not available (NA) for IR-JI, n = 4 to 10 for IR JC, n = 4 to 6 or not 
available (NA) for IR-JC PN. * P < 0.05, * * P < 0.01, vs sham-operated rats based on non-parametric Kruskal-
Wallis test followed by Dunn’s adjusted multiple comparisons.
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of plasma ghrelin concentration whereas no meal-induced inhibition of ghrelin concentration was observed in 
jejuno-ileal SBS patients (Fig. 6A).
Fasting plasma GLP-1 (3.286 ± 0.706 for SBS patients vs 1.553 ± 0.063 for controls, P < 0.05 in Mann-Whitney 
test) and GLP-2 (3.664 ± 0.716 for SBS patients vs 1.394 ± 0.252 for controls P < 0.05 in Mann-Whitney test) con-
centrations were both higher in SBS patients than in controls subjects (see also Supplemental Figure S2C,E). These 
increases were similar in jejuno-colonic and jejuno-ileal SBS patients (Fig. 6C,E). After the calibrated meal, the 
average plasma levels of these two hormones remained higher in SBS patients than in control subjects (Fig. 6C,E 
and supplemental Figure S2C,E), but the calculated incremental AUC (iAUC), reflecting the postprandial secretion 
response, did not differ significantly between patients and controls (Fig. 6D,F and Supplemental Figure S2D,F).
Figure 4. Unchanged number of PYY and GLP-1 positive cells but enhanced levels of proglucagon and 
Pyy mRNA after intestinal resection in rats. (A,B) Representative photomicrographs of GLP-1 (A) and PYY 
(B) immunostaining on colon mucosa sections from sham-operated and IR-JC rats (cytoplasm of GLP-1 or 
PYY cells are stained in brown), scale bar:50 μ m. (C,D) Quantification of GLP-1 (C) and PYY (D) positive 
cells per area in mm2. Data are represented as mean ± SEM of n = 4 for sham, n = 4 or not available (NA) for 
IR jejuno-ileal (JI), n = 5 for IR jejuno-colonic (JC), n = 6 for for IR jejuno-colonic with PN (JC-PN). (E–F) 
Colonic mucosa mRNA levels of proglucagon (Gcg) (E) and Pyy (F) normalized to L19, 7 days after surgery. 
Data are represented as mean ± SEM of n = 6 for sham, n = 5 for IR-JI, n = 9 for IR-JC, n = 6 for IR-JC with 
PN. * P < 0.05, * * P < 0.01, * * * P < 0.001 vs sham-operated rats and #P < 0.05 ##P < 0.01 vs IR-JC based on non-
parametric Kruskal-Wallis test followed by Dunn’s adjusted multiple comparisons.
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Fasting plasma PYY concentration was three times higher in SBS patients than in controls (P < 0.01 in 
Mann-Whitney tests) (Supplemental Figure S2G). This concentration increased significantly after a calibrated 
meal remaining higher in SBS patients than in controls. Accordingly, the calculated iAUC was significantly larger 
than that for controls (P < 0.01) (Supplemental Figure S2H). The difference in PYY levels (Fig. 6G) and PYY 
iAUC (P < 0.01) (Fig. 6H) with respect to controls was significantly greater in jejuno-colonic SBS patients than 
in those with jejuno-ileal anastomosis. Consistent with these observations, PYY levels were inversely correlated 
with the length of the remaining small bowel in SBS patients (Spearman coefficient: − 0.76; P < 0.05). However, 
no correlations were found between circulating PYY, GLP-1 or ghrelin levels and daily oral intake or hyperphagic 
status in SBS patients.
Discussion
This study is the first to demonstrate an increase of plasma ghrelin levels, major changes in the mRNA levels of 
hypothalamic orexigenic AgRP and NPY neuropeptides, and the elevation of PYY, together with GLP-2 and GLP-1, 
in rats with large intestinal resection including ileum, that are preclinical models of SBS. We also found that 
SBS patients had higher fasting and postprandial circulating ghrelin and PYY levels than controls, in particular 
patients with jejuno-colonic anastomosis, further emphazing the relevance of our preclinical model.
Since morphological and hormonal secretion adaptations have been reported to be maximal in different rat 
models of resection between day 4 and day 12 after intestinal resection11,27,28, the experimental period for the rat 
model was set up at 7 days. The colonic morphological adaptation observed in our IR-JC model are in agreement 
with previous reports for patient with jejuno-colonic anastomosis, i.e increase of crypt depth and of proliferating 
cell number with a controlled hyperplasia29 and increased GLP-2 secretions3.
Figure 5. Expression of mRNA coding for hypothalamic orexigenic (AgRP, NPY) and anorexigenic 
(POMC, CART) neuropeptides after intestinal resection in rats. Expression of (A) Agrp, (B) Npy, (C) Pomc 
and (D) Cart mRNA normalized to Hprt mRNA in hypothalamus in IR jejuno-ileal (JI), IR jejuno-colonic (JC), 
IR jejuno-colonic with PN (JC-PN) and sham-operated (Sham) rats 7 days after surgery. Data are represented as 
mean ± SEM of n = 6 for sham, n = 5 for IR-JI, n = 10 for IR-JC, n = 6 for for IR-JC with PN.* P < 0.05,  
* * * P < 0.001 vs sham-operated rats based on non-parametric Kruskal-Wallis test followed by Dunn’s adjusted 
multiple comparisons.
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Ghrelin is a well-known physiological hunger signal30,31 playing a major role in meal initiation21. 
Ghrelin-induced hunger involves the activation of central orexigenic pathways32 and stimulation of the expression 
of AgRP and NPY within the hypothalamus24,33,34. Higher levels of fasting ghrelin and of mRNA coding for orex-
igenic neuropeptides (AgRP and NPY) suggests a role for ghrelin in the activation of central orexigenic signals in 
IR jejuno-colonic rats. The lower levels of circulating leptin (an anorexigenic hormone) may also have contributed 
to the higher expression of the orexigenic neuropeptide23 in these IR rats. Of note, in a previous report36, and in 
our study, leptin concentrations in SBS patients was low but not different from controls. Furthermore, Molina et al. 
demonstrated that leptin concentrations did not correlate with hyperphagia in short bowel-patients36.
The central and peripheral variations of mRNA or peptide levels may also reflect the nutritional status of 
the rats. Ghrelin plays a role in long-term energy balance regulation, protecting against prolonged energy 
deficiency32. Indeed, prolonged starvation increases plasma ghrelin concentration in mice37 and may also influ-
ence NPY and AgRP mRNA levels38. We observed no hyperphagia in the IR rats during these 7 days of adaptation 
and all IR rats lost weight. Furthermore, the IR jejuno-colonic rats without PN, which are the leanest rats, had the 
highest levels of orexigenic signals suggesting that this may be an undernutrition response to promote food intake. 
IR jejuno-colonic rats with PN were heavier than jejuno-colonic rats without PN. Parenteral nutrition may ensure 
better hydration and improve energy balance by partially compensating for malabsorption, despite providing a 
moderate amount of calories. But, IR-JC rats with PN also exhibited significant increase in their orexigenic signals 
compared to IR jejuno-ileal rats even if these two groups had similar body weight. Overall, these observations 
suggest that the specific environment created by connecting the jejunum to the colon (including modifications 
of the lumen contents of nutrients, biliopancreatic secretions and microbiota metabolites) may trigger a specific 
activation of peripheral and central orexigenic cues beyond the known effect of undernutrition/starvation.
Evidence for the clinical relevance of these findings was provided by the study in human SBS patients. Indeed, 
these patients, who were not undernourished, had similar levels of leptin than healthy subjects and had high 
plasma concentrations of active ghrelin, with fasting and postprandial active ghrelin concentrations higher in 
jejuno-colonic SBS patients than in control individuals. In SBS patients, the postprandial inhibition of ghrelin 
levels was delayed, suggesting that this hunger signal persisted after the initiation of the meal in these patients. 
It remains unclear whether these persistently high ghrelin levels could induce hyperphagia in the long-term. 
Despite these differences, no relationships were found between ghrelin concentrations and the amount of ingested 
calories or the presence of hyperphagia, possibly because of the small number of SBS patients in this study. 
Further evaluation in a larger cohort of SBS patients would be required to unveil such relations.
The average concentrations of GLP-2, GLP-1 and PYY were systematically increased in IR rats, consistent with 
data reported for SBS patients (this study and3). Signals of hunger and satiety would be expected to operate in 
opposite ways. However, this does not appear to be the case here, given the concomitantly high concentrations of 
anorexigenic14 PYY and GLP-1 and orexigenic ghrelin found in IR rats and SBS patients. As suggested by others 
for GLP-139,40, the high circulating concentrations of PYY, GLP-1 and GLP-2 may affect principally gastrointes-
tinal tract functions rather than the central nervous system. In particular, these hormones decrease intestinal 
motility and transit time18, increasing the time for which nutrients are in contact with the remaining epithelium 
and thereby optimizing their distribution and absorption along the gastrointestinal tract. GLP-2 and PYY can also 
SBS patients 
(sex) Age BMI
Remnant jejunum/ 
ileum length (cm)
Remnant 
colon (%)
Delay since 
continuity 
restablishment 
(months)
Total oral 
intake 
(kcal/day)
PN/Week 
(n)
PN support 
(kcal/perfusion)
REE  
(kcal/day)
Oral  
intake /REE
Leptin 
(ng/ml)
Prealbumin 
(g/l)
P1 (M) 50 22 10/40 (SBS-JI) 100 12 3000 2 1612 1442 2,1 2,2 0,305
P2 (F) 59 16 20/0 (SBS-JC) 75 132 2200 4 2450 1070 2,1 2,2 0,194
P3 (F) 52 20 20/50 (SBS-JI) 100 24 2200 0 0 1188 1,9 1,99 0,163
P4 (F) 49 19 12/10 (SBS-JI) 100 96 3600 3 1498 1192 3,0 3,09 0,221
P5 (F) 39 23 70/5 (SBS-JI) 100 60 1500 0 0 1419 1,1 14,5 0,187
P6 (F) 32 19 0/0 (SBS-JC) 50 12 840 7 1910 1348 0,6 2,71 0,313
P7 (M) 73 20 10/40 (SBS-JI) 100 96 3000 0 0 1214 2,5 1,99 0,263
P8 (M) 57 19 15/0 (SBS-JC) 50 120 1600 5 1662 1195 1,3 4,56 0,289
P9 (F) 63 25 80/0 (SBS-JC) 50 12 2500 2 1498 1307 1,9 43,18 0,288
Median 
[25–75]
52 
[49–59]
20 
[19–22]
15  
[10–45]/5 [0–40]
100 
[50–100]
60  
[12–96]
2200 
[1600–3000]
2  
[0–4]
1498  
[0–1662]
1214 
[1192–1348]
1,9  
[1,1]
2,71 
[2,2–4.56]
0,276 
[0,194–0,289]
Table 1.  Clinical and nutritional characteristics of SBS patients. BMI: body mass index (Kg/m2). 
SBS-JI = SBS patients with jejuno-ileal anastomosis, SBS-JC = SBS patients with jejuno-colonic anastomosis. 
Remnant jejunum and ileum length and colon in continuity were expressed in cm and in % of common colon 
length, respectively. Delay was in months from the last surgery establishing an anastomosis between the 
jejunum and the remaining colon. Total oral was expressed in Kcal/day. Parenteral nutrition (PN) support was 
expressed in number (n) of perfusion per week (PN/week) and kcal/perfusion. Resting energy expenditure 
(REE) was expressed in kcal/day. Hyperphagia is defined as oral intake/REE > 1.5. Plasma levels of leptin are in 
ng/mL and prealbumin are in g/L. Values are median and 25th and 75th percentile. Etiology of SBS were arterial 
mesenteric infraction (n = 5), volvulus (n = 1), intestinal occlusion (n = 1) and surgical complications (n = 3) 
with no residual lesions of the remnant intestine.
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Figure 6. Increased fasting and post-prandial levels of plasma active Ghrelin, GLP-1, GLP2 and PYY in 
SBS patients. Plasma concentrations and secretory response to a calibrated meal (750 kcal) in SBS jejuno-ileal 
(JI) and SBS jejuno-colonic (JC) patients compared to healthy subjects (C) of: (A,B) active ghrelin (pg/mL)  
before (T0) and after (T30, T90) the meal (A) and ghrelin secretory response expressed as the total area under 
the curve (AUC) (B) GLP-1 (pg/mL) before (T0) and after (T30, T90) the meal (C) and GLP-1 secretory 
response expressed as the incremental area under the curve (iAUC) (D); (E,F) GLP-2 (pg/mL) before (T0) and 
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improve water and electrolyte absorption within the colon41,42. More specifically GLP-2 is also well known for its 
intestinotrophic effect12,18, and its increase could support, at least partially, the elevation of the colonic surface 
area we observed. Thus, this enhanced secretion of gut hormone reflects adaptive intestinal response, to improve 
overall digestion, absorption of water and nutrients and the epithelial surface available for this absorption.
The increase of fasting and postprandial secretion of PYY in SBS patients (this study and ref. 4) was larger in 
jejuno-colonic than in jejuno-ileal SBS patients and rats compared to control. No such differences were observed 
for GLP-1 and GLP-2 levels. Enteroendocrine cells are distributed from the duodenum to the colon but cells 
producing PYY are mostly restricted to the ileum and colon, and recently, it has been shown in rat that the 
highest concentrations of PYY along the gastrointestinal tract are found in the distal ileum and proximal and 
distal colon43. The higher PYY levels could result from an increase in the number of cells producing PYY due 
to morphological adaptation of the residual colon mucosa. The densities of PYY (and GLP-1) producing cells 
in colon were not affected in IR rats, suggesting that the homeostasis of epithelial cell differentiation was main-
tained in the colon of resected rats. But, the remaining colon mucosa in jejuno-colonic IR rats was hyperplasic 
with an enlarged number of proliferating cells and such changes were not observed in the colon mucosa when 
part of the ileum was preserved. A direct consequence of this colonic overgrowth would be a local increase in 
the number of enteroendocrine cells that in turn may contribute to the higher plasma concentrations of gut hor-
mones. Alternatively, the colonic hormones-producing cells, and especially the PYY producing cells, may also 
have become highly responsive to the new environment created by the direct connection of the jejunum to the 
residual colon. The lumen of the residual colon typically contains large amounts of undigested nutrients5 and a 
dysbiotic microbiota6,8,44, and is thought to display changes in the fermentative activity generating short-chain 
fatty acids (SCFAs). SCFAs can modulate the function of enteroendocrine cells secreting GLP-1/GLP-2/PYY 
in vitro45,46 and possibly in vivo46,47. Bile acids could also participate to the increased colonic production of GLPs 
and PYY48,49, as well as to the increase number of proliferating cells50, observed in jejuno-colonic individuals. 
Whether the bile acids are present in different amount and composition in the colonic lumen content of the 
jejuno-ileal, jejuno-colonic and sham operated rat remain to be evaluated.
In conclusion, we demonstrate that SBS is associated with an increase in fasting plasma ghrelin concentration 
and an induction of orexigenic signals in the hypothalamus, in a rat model with jejuno-colonic anastomosis and 
that post-prandial ghrelin inhibition is impaired in SBS patients. The induction of peripheral gut hormones, 
such as PYY, is stronger in the absence of the ileum. Intestinal resection with jejuno-colonic anastomosis creates 
a specific environment promoting increase hunger signals and improving gastrointestinal functions associated 
with nutrient absorption. Further studies are required to determine whether these changes are correlated with the 
development of hyperphagia, a good prognosis for weaning off of PN.
Materials and Methods
This study followed accepted ethical, scientific and medical standards and was conducted in accordance with 
recognized international standards, including the principles of the Declaration of Helsinki.
Animal studies. All experimental procedures were performed in accordance with the European Community 
guidelines and were approved by and the Paris Nord local ethics committee and the Ministry of Education and 
Research (N°02285.01).
6-week-old male Wistar rats (n = 28) weighing 250–300 g (Elevage Janvier, Le Genest-St-Isle, France) were 
used. The animals were housed in cage with free access to standard rat chow diet (C1314 Altromin, Genestil, 
Royaucourt, France) and water, and maintained under standardized temperature (23 °C ± 1 °C) and 12 h 
light-dark cycles (lights on at 7:00 a.m.). Animals were allowed to acclimatize to their environment for 7 days 
before experimentation.
Surgical and experimental procedure. On the day of surgery, rats were randomly assigned to undergo resection 
of 70% of the small bowel with jejuno-ileal anastomosis (IR-JI), 80% of small bowel including the ileum, ile-
ocecal valve and 20% of colon with jejuno-colonic anastomosis (for IR-JC), or a jejuno-jejunal transection with 
re-anastomosis (Sham) (Fig. 1A). Twelve hours before surgery, animals were fasted but allowed ad libitum access 
to water. They were anesthetized by intraperitoneal injection of pentobarbital sodium (Ceva, Libourne, France). 
Standard aseptic procedures were used throughout the surgery. Intestinal length was measured in a standardized 
method. The bowel was resected 15 cm distal to the ligament of Treitz to either 3 cm distal to the cecum for IR-JC 
rat groups or to 10 cm proximal to the cecum for IR JI rat groups and followed respectively by jejuno-colonic or 
jejuno-ileal anastomosis with 6–0 Prolene running sutures. Sham-operated rats underwent a jejuno-jejunal tran-
section at 15 cm below the ligament of Treitz and re-anastomosed. Animals received subcutaneously Xylocaïne 
1% (100 μ l/100 g) (Astra, France) and Penicillin G (20,000 units/kg) (Panpharma, Luitre, France) to prevent post-
operative pain and infections. Subcutaneous injection of 10 ml Bionolyte G5 (Sodium chloride [0.4%], Glucose 
[5.5%], Potassium Chloride [0.2%]) (Baxter, Maurepas, France) was given to prevent postoperative dehydration. 
Liquid diet (Nutrison, Nutricia, France) was available ad libitum 48 h after surgery. The IR jejuno-colonic rats 
after (T30, T90) the meal (E) and secretory response expressed as the iAUC (F PYY (pg/mL) before (T0) and 
after (T30, T90) the meal (G), and secretory response expressed as the iAUC (H). All values are expressed as 
the mean ± S.E.M of n = 5 for healthy subjects, n = 5 for jejuno-ileal SBS patients and n = 4 for jejuno-colonic 
SBS patients. * P < 0.05, * * P < 0.01, * * * P < 0.001 vs healthy subjects and #P < 0.05, ##P < 0.01 and ###P < 0.001 
vs jejuno-ileal SBS patients based for A, C, E, G, on Bonferroni’s multiple comparisons test and for B, D, F, H on 
non-parametric Kruskal-Wallis test followed by Dunn’s adjusted multiple comparisons.
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were under oral nutrition without or with PN through a catheter implanted in the jugular vein. PN diet, prepared 
aseptically, was perfused 48 h after surgery via a syringe pump (Precidor-Infors AG Basel) at 1.5 ml/h during 8 h 
daily, providing 12 kcal/day. Free access to food and PN administration were restored 48 hours after surgery and 
total calorie intake was calculated daily.
Previous studies have reported maximal intestinal morphological changes between day 4 and 12 after the 
surgery11,27.Thus, we set 7 days as the experimental period for this study. Body weight was monitored daily and 
food intake was determined from day 2 to 7 post-surgery. At day 7, overnight fasted rats were anesthetized; blood 
was collected in chilled tubes containing heparin or heparin and dipeptidyl peptidase IV (DPP-IV) inhibitor 
(Roche Applied Science). Plasma was aliquoted and stored in − 80 °C until analyses. Then the rats were sacrificed, 
hypothalamus and intestinal mucosa scrappings were collected and rapidly frozen until extraction of total ARN 
for RTq-PCR analyses. Other intestinal segments were formalin-fixed overnight and embedded in paraffin for 
classical histology and immunohistochemistry studies (see Supplementary Material).
Quantification of gene expression in colon mucosa and hypothalamus. Total RNA was extracted from unfrozen 
colon mucosa scrappings and from hypothalamus tissue with Trizol reagent (Invitrogen, Saint Aubin, France). 
After reverse transcription with 8 μ g total RNA, RTq-PCR real-time qPCR was performed in duplicate for each 
cDNA, using specific primers and the ABI PRISM 7000 sequence detection system and TaqMan universal PCR 
technology as described in details in Supplementary Material and compared to mean target gene expression of 
sham operated rats as calibrator samples. Fold induction was calculated using the comparative 2−Δct Method.
Clinical study. Human subjects. Nine adult patients with SBS were recruited from our tertiary care center 
for intestinal failure (Beaujon Hospital). They gave informed consent for participation to the study. The protocol 
was approved (No. 15–046) by the Institutional Review Board-IRB-00006477- of HUPNVS, Paris 7 University, 
APHP.
The patients were in a steady state, with their last surgery realized more than 6 months before the blood 
test. They all were on a non-restricted oral diet and 6 of them had PN dependence. Criteria for inclusion were 
extensive small bowel resection, with a remnant small bowel length < 150 cm, with some colon in continuity 
(jeuno-colonic anastomosis) or with ileum in continuity (jeuno-ileal anastomosis). Criteria for exclusion were 
upper gastrointestinal tract surgery, small bowel lesions in the remnant gut, organ failure other than digestive, 
evolutive neoplasia, intestinal fistulae and treatment by growth hormone, GLP-2, steroids or immunosuppressive 
therapy in the 4 months preceding the study. The patients had no signs of sepsis and no antibiotherapy.
Five adult healthy subjects with normal BMI (between 18.5–24.9 kg/m2) who gave their informed consent for 
the study were also recruited (ANSM authorization B131095–81). Procedures followed were in accordance with 
the ethical standards of the Helsinki Declaration of 1975, as revised in 1983.
Study design. The blood samples were collected in SBS and control subjects during their routine monitoring 
after an overnight fast (SBS on PN receiving saline solution to avoid dehydration), before (T0), 30 and 90 min 
after consumption of a standardized breakfast of 725 kcal (100 g of bread, 20 g of butter, 20 g of jam, 30 g of French 
emmental, 20 g of powder skimmed milk, 10 g of sugar, 250 ml of tea or coffee and 500 ml of Vichy St-Yorre water). 
Blood samples were drawn in EDTA tube Vacutainer (Becton Dickinson, France) containing DPP-IV inhibitor 
(DPP-IV-010, Millipore) and serine protease inhibitor, 4-(Aminoethyl)-benzenesulfolnyl fluoride hydrochloride 
or Pefabloc (Roche Applied Science). Samples were centrifuged between 863 to 2000 g for 10 min. Aliquoted 
plasma was stored in − 80 °C until analyses.
Plasma hormone analyses. Human and rat plasma concentrations of PYY, GLP-1, GLP-2 and ghrelin were 
quantified as described in details (Supplementary Material). The hormone assessment results were expressed as 
absolute value and incremental area under the curve (iAUC) calculated by subtracting baseline levels from all 
subsequent readings or total area under the curve (tAUC) for ghrelin.
Statistical analyses. All values are expressed as the mean ± S.E.M. Non-parametric tests were used: 
Mann-Whitney test to compare two groups and Kruskal-Wallis test followed by Dunn’s adjusted multiple com-
parisons to compare more than two groups were performed using GraphPad Prism version 6.0 for Windows 
(GraphPad Software, San Diego, CA, USA). A value of P < 0.05 was considered statistically significant.
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